Mitomycin (Mitomycin) 10 mg

Indicated for the treatment of:

• Superficial Bladder Cancer: Administered intravesically (directly into the bladder) after transurethral resection (TURBT).
• Gastric (Stomach) and Pancreatic Cancer: Used in combination chemotherapy.
• Anal and Esophageal Carcinomas.

⚠️ DANGER: Potent Vesicant! Extravasation causes severe tissue necrosis and sloughing.

Administration Routes:

• 💉 Intravenous (IV): Slow injection to avoid vein damage.
• 💧 Intravesical: Instilled into the bladder via catheter. The patient must retain the fluid for 1-2 hours, rotating positions to ensure contact with the entire bladder lining.

• Thrombocytopenia or coagulation disorders (bleeding tendency).
• For Intravesical Use: Perforation of the bladder wall (risk of chemical peritonitis).
• Pregnancy and breastfeeding.

Warning: Delayed Cumulative Toxicity.

Bone marrow suppression (low platelets and white blood cells) typically occurs 4 to 6 weeks after therapy, much later than other chemotherapy drugs.

Other reactions:

• Hemolytic Uremic Syndrome (HUS): Renal failure (rare but serious).
• Pulmonary Toxicity: Shortness of breath.
• Chemical Cystitis (bladder irritation).